Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity

J Allergy Clin Immunol. 2018 Dec;142(6):1983-1987. doi: 10.1016/j.jaci.2018.07.030. Epub 2018 Aug 17.

¹ Copenhagen Center for Glycomics and Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
² Global Research, ALK-Abelló, Hørsholm, Denmark.
³ Department of Plant and Environmental Biology, Glyco section, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
⁴ Center for Cancer Immune Therapy, Department of Hematology, Herlev Gentofte Hospital, Herlev, Denmark.
⁵ Center for Cancer Immune Therapy, Department of Hematology, Herlev Gentofte Hospital, Herlev, Denmark; Department of Immunology and Microbiology and Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁶ Department of Immunology and Microbiology and Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁷ Copenhagen Center for Glycomics and Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: [email protected].

No abstract available

Publication types